Table 1. Weighted mean difference or odds ratio (95% CI) of pairwise meta-analysis.
| Studies | Comparison | Pairwise meta-analysis | ||
|---|---|---|---|---|
| WMD/OR (95% CI) | I2 | Ph | ||
| Efficacy | ||||
| PFS (months) | ||||
| 2 studies | A vs B | −1.64 (−1.82∼–1.45) | 63.3% | 0.099 |
| 2 studies | A vs E | −1.21 (−1.99∼–0.42) | 97.7% | < 0.0001 |
| OS (months) | ||||
| 3 studies | A vs B | −1.83 (−2.08∼–0.57) | 96.6% | < 0.0001 |
| 2 studies | A vs E | −0.60 (−0.58∼–0.42) | 0.0% | 0.809 |
| ORR | ||||
| 2 studies | A vs E | 0.62 (0.40∼0.97) | 0.0% | 0.980 |
Notes: PFS and OS are stated as WMD (95% CI), while ORR and DCR are presented as OR (95%CI). 95% CI = 95% confidence interval; WMD = Weighted mean difference; OR = Odds ratio; PFS = progression-free survival; OS = overall survival; ORR = overall response rate; DCR = disease control rate; A = Erlotinib + Placebo; B = Erlotinib + Tivantinib; E = Erlotinib + Sunitinib.